| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.6M | — |
| Cost of Revenue | $797K | — |
| R&D Expense | $81.6M | +13.4% |
| SG&A Expense | $61.5M | +73.3% |
| Operating Income | -$36.4M | +66.1% |
| Pre-tax Income | -$37.1M | +63.3% |
| Income Tax | $310K | +297.4% |
| Net Income | -$37.5M | +63.0% |
| EPS (Basic) | -$0.19 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $55.7M | -43.9% |
| Accounts Receivable | $1.1M | — |
| Inventory | $2.8M | — |
| Current Assets | $112.2M | -8.1% |
| Total Assets | $146.4M | -0.6% |
| Current Liabilities | $32.9M | +43.8% |
| Long-term Debt | $75.0M | +36.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$130.9M | -35.6% |
| Capital Expenditures | $326K | +443.3% |
| Investing Cash Flow | $67.0M | +550.1% |
| Financing Cash Flow | $20.3M | -77.1% |
| Free Cash Flow | -$131.2M | -35.9% |
| +66.7% |
| EPS (Diluted) | -$0.19 | +66.7% |
| Total Liabilities |
| $124.3M |
| +29.3% |
| Stockholders' Equity | $22.1M | -56.7% |